Abstract:Abstract Histone deacetylases (HDACs) are overexpressed in various types of primary human cancer and have become attractive targets for cancer therapy. This study aimed to evaluate the cytotoxic properties of three HDAC inhibitors (suberoylanilide hydroxamic acid (SAHA, or Vorinostat), Valproic Acid (VPA) and CAY10603) and compare them to Paclitaxel (PTX), a chemotherapy agent used to treat Triple Negative Breast Cancers (TNBCs). In the present study, drug response in the MDA-MB-231, MDA-MB-468, and MCF-10A cell lines was evaluated by cell viability assays. Apoptosis and cell cycle distribution were analyzed by flow cytometry. Mammospheres generated from MDA-MB-231 and MDA-MB-468 breast cancer cells were also subjected to drug treatment; their response was assessed under both normoxic and hypoxic conditions. We found that SAHA and CAY10603 inhibited breast cancer cell viability without significantly affecting MCF-10A cells. SAHA, CAY10603, and VPA all arrested a significant percentage of MDA-MB-231 cells at G2/M phase after 24h compared to controls. TNBC cells experienced an increase in both early and late apoptosis following treatment with the most effective concentrations of SAHA, CAY10603, and VPA (1.8μM, 2μM, and 0.4mM, respectively). SAHA proved to be the most effective drug for induction of apoptosis compared to the control, followed by CAY10603 (8.26% and 6%, 3.67%). In both TNBCs and mammospheres under hypoxic conditions, SAHA and CAY10603 down regulated HIF-1α expression significantly, but PTX did not. In contrast, VPA and PTX down regulated CTNNB1 gene expression. This study indicates that epi-drugs exert an anti-tumor effect on TNBCs, suggesting a potential role for HDAC inhibitors as novel therapeutics for breast cancer patients. Citation Format: Golnaz Asaadi Tehrani, Becca Kubick, Meenal Datta. Antitumor effects of histone deacetylase inhibitors on breast cancer cell viability and mammosphere formation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4590.

Trichostatin A Inhibits Proliferation of Triple Negative Breast Cancer Cells by Inducing Cell Cycle Arrest and Apoptosis.

HDAC Inhibitor TSA Induced Apoptosis and Growth Arrest in Breast Cancer Cells

Molecular Mechanisms of Trichostatin A Inhibiting the Proliferation of Breast Cancer Cells

Histone Deacetylase Inhibitor Trichostatin A Suppresses Cell Proliferation and Induces Apoptosis by Regulating the PI3K/AKT Signalling Pathway in Gastric Cancer Cells.

Targeting HSP 90-HDAC 6 Regulating Network Implicates Precision Treatment of Breast Cancer

Histone Deacetylase Inhibitor, Trichostatin A Induces Ubiquitin-Dependent Cyclin D1 Degradation in Mcf-7 Breast Cancer Cells

Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer

Histone Deacetylase Inhibitors Suppress Mutant P53 Transcription Via HDAC8/YY1 Signals in Triple Negative Breast Cancer Cells.

The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells

Histone Deacetylase Inhibitor Trichostatin A and Autophagy Inhibitor Chloroquine Synergistically Exert Anti-Tumor Activity in H-ras Transformed Breast Epithelial Cells

Data from Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer

Inhibition of ACAA1 Restrains Proliferation and Potentiates the Response to CDK4/6 Inhibitors in Triple-Negative Breast Cancer

The Histone Deacetylase Inhibitor Trichostatin A Induces Cell Cycle Arrest and Apoptosis in Colorectal Cancer Cells Via P53-Dependent and -Independent Pathways

Sensitization to γ-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells

Abstract 4590: Antitumor effects of histone deacetylase inhibitors on breast cancer cell viability and mammosphere formation

HDAC inhibitors target IRS4 to enhance anti‐AR therapy in AR‐positive triple‐negative breast cancer

Sp1‐mediated Epigenetic Dysregulation Dictates HDAC Inhibitor Susceptibility of HER2‐overexpressing Breast Cancer

Trichostatin A reverses epithelial-mesenchymal transition and attenuates invasion and migration in MCF-7 breast cancer cells

Trichostatin C Synergistically Interacts with DNMT Inhibitor to Induce Antineoplastic Effect via Inhibition of Axl in Bladder and Lung Cancer Cells

Research of Trichostatin A in Treating Bladder Cancer

Trichostatin A Promotes Bladder Cancer Cell Apoptosis And Inhibits Cell Autophagy Through Mek/Erk Signaling Pathway